

1 **FALSE-NEGATIVE RESULTS OF INITIAL RT-PCR ASSAYS FOR COVID-19: A SYSTEMATIC REVIEW**

2

3 **AUTHORS**

4 Ingrid Arevalo-Rodriguez, MSc, PhD¹; Diana Buitrago-Garcia, MSc², Daniel Simancas-Racines, MD,
5 PhD³, Paula Zambrano-Achig, MSc⁴, Rosa Del Campo, MSc, PhD⁵, Agustín Ciapponi, MD, PhD⁶, Omar
6 Sued, MD⁷, Laura Martínez-García, MSc⁸, Anne Rutjes, PhD⁹, Nicola Low, PhD¹⁰, Jose A Perez-Molina,
7 MD, PhD¹¹, Javier Zamora, MSc, PhD^{12,13}

8

- 9 1. Clinical Biostatistics Unit, Hospital Universitario Ramón y Cajal, IRYCIS, CIBER of
10 Epidemiology and Public Health, Madrid, Spain.
- 11 2. Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland.
- 12 3. Centro de investigación en Salud Pública y Epidemiología Clínica (CISPEC). Facultad de
13 Ciencias de la Salud “Eugenio Espejo”, Universidad UTE, Ecuador.
- 14 4. Centro de investigación en Salud Pública y Epidemiología Clínica (CISPEC). Facultad de
15 Ciencias de la Salud “Eugenio Espejo”, Universidad UTE, Ecuador.
- 16 5. Department of Microbiology, Ramón y Cajal University Hospital, Ramón y Cajal Health
17 Research Institute (IRYCIS), Madrid, Spain.
- 18 6. Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
- 19 7. Fundación Huésped, Buenos Aires, Argentina.
- 20 8. Department of Microbiology, Ramón y Cajal University Hospital, Ramón y Cajal Health
21 Research Institute (IRYCIS), CIBER of Epidemiology and Public Health, Madrid, Spain.
- 22 9. Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland.
- 23 10. Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland.
- 24 11. National Referral Centre for Tropical Diseases, Infectious Diseases Department, Hospital

25 Universitario Ramón y Cajal, Insituto Ramón y Cajal de Investgación Sanitaria, Madrid, Spain.

26 12. Clinical Biostatistics Unit, Hospital Universitario Ramón y Cajal, IRYCIS, CIBER of
27 Epidemiology and Public Health, Madrid, Spain.

28 13. Barts and the London School of Medicine and Dentistry, Queen Mary University London
29 (UK)

30

31 **Corresponding author:**

32 Ingrid Arevalo-Rodriguez

33 Clinical Biostatistics Unit, Hospital Universitario Ramón y Cajal, IRYCIS

34 CIBER of Epidemiology and Public Health

35 Madrid, Spain

36 Email: ingrid.arevalo@salud.madrid.org

37 ORCID ID: 0000-0002-7326-4504

38 **ABSTRACT**

39 **Background:** Cases with negative reverse transcription-polymerase chain reaction (RT-PCR) results
40 at initial testing for suspicion of SARS-CoV-2 infection, and found to be positive in a subsequent test,
41 are considered as RT-PCR false-negative cases. False-negative cases have important implications for
42 COVID-19 management, isolation, and risk of transmission. We aimed to review and critically
43 appraise evidence about the proportion of RT-PCR false-negatives at initial testing for COVID-19.

44 **Methods:** We performed a systematic review and critical appraisal of literature with high
45 involvement of stakeholders in the review process. We searched on MEDLINE, EMBASE, LILACS, the
46 WHO database of COVID-19 publications, the EPPI-Centre living systematic map of evidence about
47 COVID-19, and the living systematic review developed by the University of Bern (ISPM). Two authors
48 screened and selected studies according to the eligibility criteria and collected data of included
49 studies (no-independent verification). Risk of bias was assessed using the Quality Assessment of
50 Diagnostic Accuracy Studies (QUADAS-2) tool. We calculated the false-negative proportion with the
51 corresponding 95% CI using a multilevel mixed-effect logistic regression model using STATA 16®.
52 Certainty of the evidence about false-negative cases was rated using the GRADE approach for tests
53 and strategies. The information is current up to 6 April 2020.

54 **Findings:** Five studies enrolling 957 patients were included. All studies were affected by several
55 biases and applicability concerns. Pooled estimation of false-negative proportion was 0.085 (95%
56 CI= 0.034 to 0.196; tau-squared = 1.08; 95% CI= 0.27 to 8.28; p<0.001); however, this estimation is
57 highly affected by unexplained heterogeneity, and its interpretation should be avoided. The
58 certainty of the evidence was judged as very low, due to the risk of bias, indirectness, and
59 inconsistency issues.

60 **Conclusions:** The collected evidence has several limitations, including risk of bias issues, high
61 heterogeneity, and concerns about its applicability. Nonetheless, our findings reinforce the need for

62 repeated testing in patients with suspicion of SARS-Cov-2 infection given that up to 29% of patients
63 could have an initial RT-PCR false-negative result.

64 **Systematic review registration:** Protocol available on OSF website: <https://osf.io/gp38w/>

65

FINAL DRAFT

66 BACKGROUND

67 On December 31, 2019, the World Health Organization (WHO) was alerted about a cluster of
68 pneumonia patients in the city of Wuhan, in China's Hubei province [1]. Chinese authorities
69 confirmed a week later the outbreak of a novel coronavirus currently called Severe Acute
70 Respiratory Coronavirus 2 (SARS-CoV-2) [2]. This new virus is the underlying cause of Coronavirus
71 Disease 2019 (COVID-19), which has become a worldwide public health emergency and reached
72 pandemic status [3]. By the time of this article's writing, the virus has spread to 212 countries and
73 territories and has caused over 85,837 deaths worldwide [4].

74 Patients with COVID-19 exhibit respiratory symptoms such as fever, cough, and shortness of breath
75 as primary manifestations [5, 6]. Although most of the cases present mild symptoms, some cases
76 have developed pneumonia, severe respiratory diseases, kidney failure and even death [7-9]. SARS-
77 CoV-2 mainly spreads through person-to-person contact via respiratory droplets from coughing and
78 sneezing, and through surfaces that have been contaminated with these droplets.[10] Recent
79 studies have suggested the presence of asymptomatic cases in cluster families, possibly transmitting
80 the virus before a virus-carrying person displays any symptom [11].

81 Because the signs of infection mentioned above are non-specific, confirmation of cases is currently
82 based on the detection of a viral sequence by reverse transcription-polymerase chain reaction (RT-
83 PCR). Different RT-PCR schemes have been proposed; all of them include the N gene that codes for
84 the viral nucleocapsid. Other alternative targets are the E gene, for the viral envelope, or the S gene
85 for the spike, and the Hel gene for the RNA polymerase gene (RdRp/Helicase) [12, 13]. Molecular
86 criteria for *in vitro* diagnosis of COVID-19 disease are heterogeneous, and usually require the
87 detection of two or more genes of SARS-CoV-2 [14].

88 RT-PCR repeated testing might be required to confirm a clinical diagnosis, especially in the presence
89 of symptoms close related to COVID-19 disease [15]. Cases with negative RT-PCR results at initial

90 testing and later found to be positive in a subsequent test are commonly considered cases with an
91 initial false-negative result. Some researchers have suggested that these failures in SARS-CoV-2
92 detection are related to multiple pre-analytical and analytical factors, such as lack of standardisation
93 to collect specimens, the time and conservation of samples until to be received in the laboratory,
94 the use of non-adequately validated assays, contamination during the procedure, insufficient viral
95 specimens and load, the incubation period of the disease, and the risk of active recombination and
96 mutation [14, 16].

97 The availability of accurate laboratory tools for COVID-19 is essential for case identification, contact
98 tracing, and optimization of infection control measures, as it was shown by previous epidemics
99 caused by SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) [17-19]. Due
100 to the COVID-19 pandemic causing an important burden on health systems around the globe, and
101 considering that a missing COVID 19 case might have severe consequences at several levels, we
102 aimed to estimate through a systematic review of the literature the proportion of false-negatives
103 related to the detection of SARS-CoV-2 using RT-PCR assays at the initial laboratory test.

104

105 **METHODS**

106 We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for
107 diagnostic test accuracy (DTA) to perform this report [20]. For the development of this systematic
108 review of literature, we used selected methods for the development of rapid reviews, such as a high
109 involvement of stakeholders in the review process (including the definition of the review question),
110 a non-independent verification of data selection and extraction, and parallelisation of tasks (that is,
111 to perform selected activities simultaneously instead of consecutively). Other review shortcuts and
112 omission of review tasks were not applied. A protocol of this review was published in the Open
113 Science Framework repository for public consultation (<https://osf.io/gp38w/>).

114 *Criteria for considering studies for this review*

115 We included observational studies (including accuracy studies, cohorts, and case series) reporting
116 the initial use of RT-PCR to the detection of SARS-CoV-2 RNA in patients under suspicion of infection
117 by clinical or epidemiological criteria. Specially, we prioritised studies enrolling consecutive patients
118 who were receiving RT-PCR as initial testing with further confirmation of SARS-CoV-2 infection
119 and/or COVID-19 diagnosis (positive/negative). We did not impose limits by age, gender, or study
120 location.

121 We aimed to include all types of RT-PCR kits, regardless of the brand/manufacturer, the RNA
122 extraction method used, the number of target gene assays assessed and cycle threshold value for
123 positivity. Studies comparing the accuracy of two or more tests for COVID-19 diagnosis were also
124 considered if we could abstract the fraction of negative test results as defined by an initial RT-PCR
125 assay.

126 We excluded studies without clear information about false-negative cases, the number of final
127 confirmed cases, or an unclear verification of negative cases. Case reports, studies based on
128 laboratory samples, and literature reviews were also excluded.

129 *Search methods for identification of studies*

130 We carried out a comprehensive and sensitive search strategy based on the proposal for the living
131 systematic review developed by the University of Bern's Institute of Social and Preventive Medicine-
132 ISPM in the following databases:

- 133 • MEDLINE (Ovid SP, 1946 to April 6th, 2020)
- 134 • Embase (Ovid SP, 1982 to April 6th, 2020)
- 135 • LILACS (iAH English) (BIREME, 1982 to April 6th, 2020)

136 We did not apply any language restrictions to electronic searches (S1 Appendix). As additional
137 sources of potential studies, we searched in repositories of preprint articles (such as Medrxiv),

138 clinical trials registries for ongoing or recently completed trials (clinicaltrials.gov; the World Health
139 Organization's International Trials Registry and Platform, and the ISRCTN Registry), and the
140 reference lists of all relevant papers. Finally, we also screened the following resources for additional
141 information:

- 142 • The WHO Database of publications on coronavirus disease (COVID-19). Available on
143 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov)
144 [novel-coronavirus-2019-ncov.](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov)
- 145 • The Living systematic map of the evidence about COVID-19 produced by EPPI-Centre.
146 Available on:
147 [http://eppi.ioe.ac.uk/cms/Projects/DepartmentofHealthandSocialCare/Publishedreviews/](http://eppi.ioe.ac.uk/cms/Projects/DepartmentofHealthandSocialCare/Publishedreviews/COVID19Livingssystematicmapoftheevidence/tabid/3765/Default.aspx)
148 [COVID19Livingssystematicmapoftheevidence/tabid/3765/Default.aspx](http://eppi.ioe.ac.uk/cms/Projects/DepartmentofHealthandSocialCare/Publishedreviews/COVID19Livingssystematicmapoftheevidence/tabid/3765/Default.aspx)
- 149 • The Living systematic review developed by the Institute of Social and Preventive Medicine-
150 ISPM from the University of Bern available on <https://ispmbern.github.io/covid-19/>

151 *Data collection and analysis*

152 For the selection of potential studies, one reviewer screened the search results based on the title
153 and abstract, with additional verification by a second reviewer (no-independent verification). We
154 retrieved the full-text copy of each study assessed as potentially eligible, and pairs of reviewers
155 confirmed eligibility according to the selection criteria (non-independent verification). In case of
156 disagreements we reached consensus by discussion. For data extraction one reviewer extracted
157 qualitative and quantitative data from eligible studies. An additional reviewer checked all the
158 extracted information for accuracy (non-independent verification of data extraction).

159 *Assessment of methodological quality*

160 We assessed the methodological quality of accuracy studies using the Quality Assessment of
161 Diagnostic Accuracy Studies (QUADAS-2) tool [21]. Due to the lack of tools to assess the risk of bias

162 associated with case series, we decided to apply the QUADAS-2 tool in case of inclusion of this type
163 of report.

164 *Statistical analysis and data synthesis*

165 For all included studies, we extracted data about the number of cases initially considered as negative
166 (i.e. false-negative cases) as well as the total of confirmed cases in further investigations. We
167 presented the results of estimated proportions (with 95% CIs) in a forest plot, in order to assess the
168 between-study variability. We aimed to calculate the false-negative rate with the corresponding
169 95% CI using a multilevel mixed-effect logistic regression model implemented in Stata 16®'s
170 `metaprop_one` command. This allowed us to estimate the between-study heterogeneity from the
171 variance of study-specific random intercepts. We assessed the heterogeneity between the results
172 of the primary studies using the Tau-square statistic. A probability value less than 0.1 ($p < 0.1$) was
173 considered to suggest statistically significant heterogeneity and preclude a pooled result of
174 numerical data.

175 We planned to investigate the potential sources of heterogeneity using a descriptive approach and
176 performing a random-effects meta-regression analysis. Anticipated sources of heterogeneity
177 included the type of specimen collected, the presence or not of clinical findings, the number of RNA
178 targets genes under assessment, and the time of symptom evolution.

179 *Summary of findings and certainty of the evidence*

180 We rated the certainty of the evidence about false-negative cases following the GRADE approach
181 for tests and strategies [22, 23]. We assessed the quality of evidence as high, moderate, low or very
182 low, depending on several factors including risk of bias, imprecision, inconsistency, indirectness, and
183 publication bias. We illustrate the consequences of the numerical findings in a population of 100
184 tested, according to three different prevalence estimates of the disease provided by the
185 stakeholders involved in this review.

186 *Patient and public involvement*

187 We involved several stakeholders in the design, conduct, and reporting of our research, including
188 general and family physicians, specialists on infectious disease and microbiologists currently
189 attending patients under suspicion of COVID 19 disease. The study protocol and preliminary results
190 are publicly available on <https://osf.io/gp38w/>.

191

192 **RESULTS**

193 Electronic searches yielded 662 references from selected databases. In addition, we obtained 186
194 additional references searching in other resources (Figure 1). Our initial screening of titles and
195 abstracts identified 61 references to assess in full text. We excluded 54 studies due to: a) case
196 reporting fewer than five patients; b) unclear information about the results of initial RT-PCR and/or
197 false-negatives; c) reviews and state-of-art; d) other reasons (S2 Appendix). Two studies were not
198 available in full-text despite requests to their authors. We included five studies in qualitative and
199 quantitative synthesis [24-28] which included 957 patients.

200 The sample size ranged from 36 to 601 confirmed cases (median 102 patients). All included studies
201 were in pre-print status. Three studies were focused on accuracy estimations [24, 26, 27], while two
202 additional studies reported information of a case series [25, 28]. Data collection of cases ranged
203 from January 6 to February 8-2020. All studies were performed in institutions based in China (Figure
204 2). The age of participants ranged from 44 to 51 years (information derived from three studies) [24,
205 25, 27]. There were 577 men versus 213 women included (Table 1). Three studies included patients
206 under suspicion of COVID-19 due to clinical findings and/or epidemiological criteria [24, 26, 27].
207 Confirmation of infection was performed after isolation of SARS-CoV-2 in any real-time RT-PCR assay
208 for 2019-nCoV, including repeated RT-PCR after negative results (two or more). Three studies
209 provided information about the proportion of confirmed cases with positive chest CT findings,

210 ranging from 74 to 98%. One study provided information about the time from the symptom onset
211 to CT scan as a proxy for the duration of disease [25], and a second one reported duration of fever
212 [27].

213 Regarding RT-PCR testing, the RT-PCR brand/manufacturer was reported by two studies [24, 25], No
214 studies reported criteria for positivity. Most of the studies based their assessment on throat
215 samples, such as pharyngeal, nasal and oropharyngeal swabs. Four studies provided information
216 about the time since the initial RT-PCR to repeated testing (Table 1).

FINAL DRAFT

217 **Table 1.** Characteristics of included studies

ID	Data collection	Setting	Age (years)	N total (male: female)	Type of specimen	RT-PCR Brand	Days from symptoms onset (days)	Interval between initial RT-PCR to additional RT-PCRs
Ai T 2020	January 6 to February 6	Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China	Mean 51 ± 15 Range of 2 to 95	601 (467:134)	Throat swab	TaqMan One-Step RT-PCR Kits from Shanghai Huirui Biotechnology Co., Ltd or Shanghai BioGerm Medical Biotechnology Co., Ltd,	Not reported	Median: 4 days (range from 4-8 days)
Bernheim A 2020	January 18 to February 2	Hospitals from four provinces in China: Nanchang (Jiangxi Province), Zhuhai (Guangdong Province), Chengdu (Sichuan province) and Guilin (Guangxi province)	Mean 45 ± 15,6	102 (61:41)	Bronchoalveolar lavage, endotracheal aspirate, nasopharyngeal swab, or oropharyngeal swab	Sansure Biotech Inc. (Changsha, China), Shanghai Zhijiang Biotechnology Co. (Shanghai, China), or Da An Gene Co. (Guangzhou, China).	Range to 0 to 12	Not reported
Fang Y 2020	January 19 to February 4	Taizhou Enze Medical Center (Group) Enze Hospital	Median 45 Interquartile range of 39-55	51 (29:22)	Throat swab, sputum	Not reported	Mean 3±3	Repeat testing was performed at intervals of 1 day or more; no further information provided
Long C 2020	January 20 to February 8	Yichang Yiling Hospital	Mean 44,8 ±18,2	36 (20:16)	Not reported	Not reported	Only duration of fever reported: 2,6 ± 1,7 days	Range from 2 to 8 days
Xie X 2020	January 16 to February 2	Database of Radiology Quality Control Centre, Hunan/ 3 cities in Hunan Province, China	Not reported	167 (Not reported)	swab test; no further details provided	Not reported	Not reported	Range from 2 to 8 days

218

219 **Quality of included studies**

220 We applied the QUADAS-II tool to all included studies to reflect critical limitations in the validity of
221 the findings (Figure 3 and S3 Appendix). The reference standard domain was the most affected by
222 the potential risk of bias due to the lack of independence between the index test and the
223 confirmation of cases (repeated RT-PCR testing). Details about the criteria for positivity were not
224 provided by all included studies, and this domain was judged as under unclear risk and unclear
225 applicability concerns. In addition, the applicability of patient selection was judged as with great
226 concerns due to most of the studies selected patients who underwent both RT-PCR and Chest CT,
227 excluding patients who can be candidates to receive the index test in the current clinical practice.

228

229 **Findings**

230 We analyse information from five studies collecting information from 957 patients confirmed to
231 have SARS-CoV-2 infection and 53 cases with RT-PCR negative findings in their initial assessment
232 (Figure 4). False-negative proportions ranged from 0.02 [24] to 0.29 [26]. Only one study provided
233 subgroup information about time since illness onset to CT scans [25], as a proxy of the time of
234 symptom evolution, with proportions ranged from 0.15 (≤ 2 days) to 0.08 (3 or more days) (Figure
235 4).

236 The pooled estimation of false-negative proportion was 0.085 (95% CI 0.034 to 0.196) estimated by
237 a mixed-effects logistic regression model. However, pooled data is affected by a considerable
238 between-study heterogeneity ($\tau^2 = 1.08$; 95% CI= 0.27 to 8.28; $p < 0.001$), since we are not
239 able to warrant that the average estimation provided by the meta-analysis is a valid and
240 representative estimation of the true value of the false-negative proportion in the current practice,
241 we instead used the range of proportions in the analysis of the certainty of the evidence using the
242 GRADE approach. A full exploration of heterogeneity was not possible given that: a) most of the

243 studies collected upper or lower respiratory specimens; b) all studies included patients with clinical
244 findings suggestive of COVID 19 disease; c) subgroup information by the time of evolution of
245 symptom was only provided by one study; and d) key information about the characteristics of the
246 index test, such as positivity criteria, were not reported. The high variability of pooled estimation
247 was not reduced with the separate estimation of false-negative proportion by type of study
248 (accuracy versus case series).

249

250 **Certainty of the evidence**

251 We use the range of false-negative proportions to develop a summary of findings following the
252 GRADE approach. The quality of the evidence was judged to be very low due to issues related to the
253 risk of bias, indirectness, and inconsistency (Figure 5). We illustrate the consequences of the range
254 of false-negative proportions in a population of 100 tested, according to three different prevalence
255 seen in the current clinical practice for participant stakeholders (30%, 50%, and 80%) (Figure 5).
256 Using a prevalence of 50%, we found that 1 to 14 cases would be misdiagnosed and then they could
257 no receive adequate clinical management, and they could require repeated testing at some point of
258 their hospitalization or even they could require other investigations for competitive diagnoses. This
259 numerical approach should be interpreted with caution due to the multiple limitations of the
260 evidence described above (Figure 5).

261

262 **DISCUSSION**

263 Our systematic review included five studies and 957 participants providing information about the
264 proportion of false-negative cases related to the detection of SARS-CoV-2 by RT-PCR assays at first
265 use. The included studies enrolled patients under suspicion of COVID 19 [24, 26, 27] or confirmed
266 COVID 19 cases [25, 28]. Almost all studies enrolled a selected sample of patients (i.e. patients with

267 findings for RT-PCR and chest CT) from several provinces of China and collected between January to
268 February 2020. We considered all studies to be affected by several sources of bias, especially related
269 to the independence between the index test and the reference standard and the unclear report of
270 key RT-PCR characteristics. A meta-analysis of the proportions using Stata® showed a considerable
271 heterogeneity not explained by the collected data, and this variability is a limitation for the full
272 interpretation of averaged proportion. As an alternative, we preferred to provide an analysis of the
273 range of false-negative proportions derived from included studies in a cohort of 100 patients tested
274 and using three different prevalence of the disease derived from the current clinical practice of our
275 participant stakeholders. Using a prevalence of 80%, we found that 2 to 23 cases would be
276 misdiagnosed and then they could not receive adequate clinical management. However, we
277 emphasized that this numerical approach should be interpreted with caution due to the multiple
278 limitations of the evidence described above (Quality of evidence: Very low).

279 Although we did not impose restrictions on population characteristics such as age, setting or
280 publication status, we noticed that our findings are limited due to all the studies were performed in
281 one country (China), and they reported data only for the beginning of the pandemic (January 2020),
282 in addition to the lack of reporting about the index test previously mentioned. RT-PCR kits in use for
283 included studies were likely the first kits developed by detection of SARS-CoV-2, and then the tests
284 currently in use might have a great technological evolution and different characteristics to those
285 of the initial tools.

286

287 Despite the scarcity of information to answer the review question, our study carried out a
288 comprehensive literature search to identify all relevant studies, including several sources of
289 unpublished literature such as pre-print repositories. Our assessment also includes a rigorous
290 assessment of potential sources of bias, a formal statistical analysis of results and a final assessment

291 of the certainty of the evidence under a well-known system (GRADE). We applied selected methods
292 associated with rapid reviews to streamline the review process, such as the involvement of
293 stakeholders in the development of the review, a non-independent verification of data selection
294 and extraction, and parallelisation of tasks (that is, to conduct selected activities simultaneously
295 instead of consecutively) [29]. We avoided the use of methods that potentially might affect the
296 quality of the review process, such as those related to limiting the search strategies, the omission
297 of quality assessment of the collected evidence and the narrative synthesis of results [29, 30].
298 Due to the permanent involvement of clinicians managing COVID 19 patients in the development of
299 this review, we were able to define a review question that responds to a clinical inquiry relevant to
300 current clinical practice [31-33]. In fact, the number of cases misdiagnosed as not having the target
301 condition is a critical figure due to the severe consequences of not treatment of missing patients.
302 This estimation also can help in the estimation of additional resources in the current clinical
303 practices to confirm a suspicious case.

304

305 **Implications for practice**

306 Our findings reinforce the need for repeated testing in patients with suspicion of being infected, due
307 to either clinical or epidemiological reasons, given that up to 29% of patients may have an initial
308 negative RT-PCR (certainty of evidence: very low). The collected evidence has several limitations in
309 terms of risk of bias and applicability; in addition, lack of reporting of several key factors remains a
310 significant constraint for analysis of collected data. A false negative result during the recovering
311 phase could have important implications for isolation and risk of transmission, although this risk is
312 reduced by the documentation of at least two negative samples before the discharge. A consequent
313 positive result could also be erroneously considered as reinfection. An update of this review when
314 new studies would be available is warranted.

315 **Implications for research**

316 Due to the multiple difficulties associated with the lack of reporting of included studies, and due to
317 the high probability of new studies being published in the short-term, we provided some
318 recommendations for future studies candidates to be included in an update of this review:

- 319 • Inclusion of a series of consecutive patients instead of selected groups, to avoid spectrum bias.
- 320 • Inclusion of a series of consecutive patients instead of selected groups, to avoid spectrum bias
- 321 • If samples /specimens are analysed, reporting of information by patient
- 322 • Description of RT-PCR scheme in use, including target genes under assessment and positivity
323 criteria
- 324 • Description of pre-analytical steps (conservation of samples, time until being sent to the
325 laboratory, training of personal)
- 326 • Clear reporting of the time since the onset of symptoms, especially for those patients with
327 clinical findings at admission
- 328 • Reporting of the number of additional RT-PCR assays performed
- 329 • Details about the application of the reference standard, including the time of administration
330 after the index test (initial RT-PCR)
- 331 • If possible, database sharing could allow re-analyses by independent researchers, including
332 individual-patient data (IPD)-meta-analysis and increasing thus the confidence on the new
333 evidence
- 334 • Add serological samples to a cohort of individuals with compatible symptoms and negative PCR
335 to warrant an independent verification of infection.

336

337

338

339 **DECLARATIONS**

340 **Contributors:** IAR, DBG, DS and JZ conceived the study. IAR, DBG, DSR, RDC, JAPM and JZ designed
341 the study. IAR, DBG, DSR, PZA screened titles and abstracts for inclusion. IAR, DBG, DSR, PZA, ,AR
342 and JZ extracted and analysed data. RDC, JAPM, AC, OS and NL assisted in the interpretation from
343 a clinical viewpoint. IAR, DBG, DSR and JZ wrote the first draft, which all authors revised for critical
344 content. All authors approved the final manuscript. IAR and JZ are the guarantors. The
345 corresponding author attests that all listed authors meet authorship criteria and that no others
346 meeting the criteria have been omitted.

347 **Funding:** Ingrid Arevalo-Rodriguez is funded by the Instituto de Salud Carlos III through the “Acción
348 Estrategica en Salud 2013-2016 / Contratos Sara Borrell convocatoria 2017/CD17/00219” (Co-
349 funded by European Social Fund 2014-2020, "Investing in your future").

350 **Competing interests:** All authors declare: no support from any organisation for the submitted work;
351 no competing interests with regards to the submitted work.


352 **Ethical approval:** Not required.

353 **Data sharing:** The study protocol is available online at <https://tinyurl.com/vvbgqya>. Most included
354 studies are publically available. Additional data are available upon reasonable request.

355

356


357 **Figure 1. PRISMA flow diagram**



358

359

360 **Figure 2. Setting- included studies**



361

362

FINAL DRAFT

363 **Figure 3. Methodological quality- QUADAS-II tool**


	<u>Risk of Bias</u>				<u>Applicability Concerns</u>		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Ai T 2020	+	?	-	+	-	?	+
Bernheim A 2020	+	?	-	?	-	?	+
Fang Y 2020	+	?	-	+	-	?	+
Long C 2020	-	?	-	+	-	?	+
Xie X 2020	?	?	-	+	?	?	+

- High
 ? Unclear
 + Low

364

365

366 **Figure 4. Forest plot included studies**



Note: Bernheim A 2020 reported time since the symptom onset to CT scan; Long C 2020 reported duration of fever.

367

368

FINAL DRAFT

369 **Figure 5. Certainty of the evidence (GRADE assessment)**

Proportion: ranged from 0.02 to 0.29	Effect per 100 patient tested			Number of participants (studies)	Certainty of the evidence (GRADE)
	Prevalence 30% Typically seen in	Prevalence 50% Typically seen in	Prevalence 80% Typically seen in		
False-negatives (patients incorrectly classified as not having COVID- 19	1 to 9	1 to 14	2 to 23	957 (5 studies)	⊕○○○ VERY LOW ^{1,2,3}

Notes= 1. Evidence downgraded one level due to risk of bias issues: index test as a part of the reference standard, unclear positivity thresholds for index test; 2. Evidence downgraded one level due to indirectness: selected population enrolled in studies; 3. Evidence downgraded one level due to inconsistency: Tau-square=1.08; 95% CI 0.27 to 8.28; p<0.001.

370

371

FINAL DRAFT

372

REFERENCES

373

- 374 1. Perrella A, Carannante N, Berretta M, Rinaldi M, Maturo N, Rinaldi L. Novel Coronavirus
375 2019 (Sars-CoV2): a global emergency that needs new approaches? European review for medical
376 and pharmacological sciences. 2020;24(4):2162-4. Epub 2020/03/07. doi:
377 10.26355/eurrev_202002_20396. PubMed PMID: 32141586.
- 378 2. Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI, et al. Potential Rapid Diagnostics,
379 Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. J Clin Med.
380 2020;9(3). doi: 10.3390/jcm9030623. PubMed PMID: 32110875.
- 381 3. Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, et al. Novel
382 coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-
383 CoV and MERS-CoV. European review for medical and pharmacological sciences. 2020;24(4):2012-
384 9. Epub 2020/03/07. doi: 10.26355/eurrev_202002_20379. PubMed PMID: 32141570.
- 385 4. World Health Organization. Coronavirus disease 2019 (COVID-19): Situation Report – 80.
386 Geneva, Switzerland: 2020.
- 387 5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
388 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-
389 6736(20)30183-5. PubMed PMID: 31986264.
- 390 6. Chen Q, Quan B, Li X, Gao G, Zheng W, Zhang J, et al. A report of clinical diagnosis and
391 treatment of nine cases of coronavirus disease 2019. J Med Virol. 2020. doi: 10.1002/jmv.25755.
392 PubMed PMID: 32162699.
- 393 7. Paules CI, Marston HD, Fauci AS. Coronavirus Infections—More Than Just the Common Cold.
394 JAMA. 2020;323(8):707-8. doi: 10.1001/jama.2020.0757.
- 395 8. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and
396 Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020. doi:
397 10.1001/jama.2020.3204.
- 398 9. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity
399 of coronavirus disease 2019: a model-based analysis. The Lancet Infectious Diseases. doi:
400 10.1016/S1473-3099(20)30243-7.
- 401 10. Azman AS, Luquero FJ. From China: hope and lessons for COVID-19 control. The Lancet
402 Infectious Diseases. doi: 10.1016/S1473-3099(20)30264-4.
- 403 11. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper
404 Respiratory Specimens of Infected Patients. N Engl J Med. 2020;382(12):1177-9. doi:
405 10.1056/NEJMc2001737. PubMed PMID: 32074444.
- 406 12. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019
407 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro surveillance : bulletin Europeen sur les
408 maladies transmissibles = European communicable disease bulletin. 2020;25(3). Epub 2020/01/30.
409 doi: 10.2807/1560-7917.es.2020.25.3.2000045. PubMed PMID: 31992387; PubMed Central PMCID:
410 PMC6988269.
- 411 13. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, et al. Molecular Diagnosis of a Novel
412 Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. Clinical chemistry. 2020;66(4):549-
413 55. Epub 2020/02/08. doi: 10.1093/clinchem/hvaa029. PubMed PMID: 32031583; PubMed Central
414 PMCID: PMC6988269.
- 415 14. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the
416 laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clinical chemistry and laboratory
417 medicine. 2020. Epub 2020/03/17. doi: 10.1515/cclm-2020-0285. PubMed PMID: 32172228.

- 418 15. Organization WH. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected
419 human cases. Geneva, Switzerland: 2020 2 March 2020. Report No.: Contract No.: WHO/COVID-
420 19/laboratory/2020.4.
- 421 16. Li D, Wang D, Dong J, Wang N, Huang H, Xu H, et al. False-Negative Results of Real-Time
422 Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome
423 Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases. *Korean*
424 *journal of radiology*. 2020;21(4):505-8. Epub 2020/03/17. doi: 10.3348/kjr.2020.0146. PubMed
425 PMID: 32174053; PubMed Central PMCID: PMC7082661.
- 426 17. Gostin LO. Public Health Emergency Preparedness: Globalizing Risk, Localizing Threats.
427 *JAMA*. 2018;320(17):1743-4. doi: 10.1001/jama.2018.16491.
- 428 18. Lin C, Ye R, Xia YL. A meta-analysis to evaluate the effectiveness of real-time PCR for
429 diagnosing novel coronavirus infections. *Genetics and molecular research : GMR*. 2015;14(4):15634-
430 41. Epub 2015/12/05. doi: 10.4238/2015.December.1.15. PubMed PMID: 26634531.
- 431 19. Sharfstein JM, Becker SJ, Mello MM. Diagnostic Testing for the Novel Coronavirus. *JAMA*.
432 2020. doi: 10.1001/jama.2020.3864.
- 433 20. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred
434 reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The
435 PRISMA-DTA statement. *JAMA*. 2018;319(4):338-96.
- 436 21. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a
437 revised tool for the quality assessment of diagnostic accuracy studies. *Annals of internal medicine*.
438 2011;155(8):529-36. Epub 2011/10/19. doi: 10.7326/0003-4819-155-8-201110180-00009. PubMed
439 PMID: 22007046.
- 440 22. Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE
441 guidelines: 21 part 1. Study design, risk of bias and indirectness in rating the certainty across a body
442 of evidence for test accuracy. *Journal of Clinical Epidemiology*. doi: 10.1016/j.jclinepi.2019.12.020.
- 443 23. Schünemann HJ, Mustafa RA, Brozek J, Steingart KR, Leeflang M, Murad MH, et al. GRADE
444 guidelines: 21 part 2. Inconsistency, Imprecision, publication bias and other domains for rating the
445 certainty of evidence for test accuracy and presenting it in evidence profiles and summary of
446 findings tables. *Journal of Clinical Epidemiology*. doi: 10.1016/j.jclinepi.2019.12.021.
- 447 24. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT and RT-PCR Testing
448 in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology*. 2020:200642.
449 doi: 10.1148/radiol.2020200642. PubMed PMID: 32101510.
- 450 25. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT Findings in
451 Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. *Radiology*. 2020:200463.
452 doi: 10.1148/radiol.2020200463. PubMed PMID: 32077789.
- 453 26. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of Chest CT for COVID-19:
454 Comparison to RT-PCR. *Radiology*. 2020:200432. doi: 10.1148/radiol.2020200432. PubMed PMID:
455 32073353.
- 456 27. Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, et al. Diagnosis of the Coronavirus disease
457 (COVID-19): rRT-PCR or CT? *European journal of radiology*. 2020;126:108961. Epub 2020/04/02. doi:
458 10.1016/j.ejrad.2020.108961. PubMed PMID: 32229322; PubMed Central PMCID:
459 PMC7102545.
- 460 28. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical 2019-nCoV Pneumonia:
461 Relationship to Negative RT-PCR Testing. *Radiology*. 2020:200343. doi: 10.1148/radiol.2020200343.
462 PubMed PMID: 32049601.
- 463 29. Arevalo-Rodriguez I, Moreno-Nunez P, Nussbaumer-Streit B, Steingart K, Gonzalez Peña L,
464 Buitrago-Garcia D, et al. Rapid reviews of medical tests used many similar methods to systematic

465 reviews but key items were rarely reported: a scoping review. *Journal of Clinical Epidemiology*.
466 2019;116:98-105.
467 30. Tricco AC, Antony J, Zarin W, Strifler L, Ghassemi M, Ivory J, et al. A scoping review of rapid
468 review methods. *BMC medicine*. 2015;13:224. Epub 2015/09/18. doi: 10.1186/s12916-015-0465-6.
469 PubMed PMID: 26377409; PubMed Central PMCID: PMC4574114.
470 31. Wilson MG, Lavis JN, Gauvin FP. Developing a rapid-response program for health system
471 decision-makers in Canada: findings from an issue brief and stakeholder dialogue. *Systematic*
472 *reviews*. 2015;4:25. Epub 2015/04/16. doi: 10.1186/s13643-015-0009-3. PubMed PMID: 25875495;
473 PubMed Central PMCID: PMC4373100.
474 32. Moore G, Redman S, Rudge S, Haynes A. Do policy-makers find commissioned rapid reviews
475 useful? *Health Res Policy Syst*. 2018;16(1):17. Epub 2018/02/28. doi: 10.1186/s12961-018-0293-1.
476 PubMed PMID: 29482643; PubMed Central PMCID: PMC5828139.
477 33. Hartling L, Guise JM, Hempel S, Featherstone R, Mitchell MD, Motu'apuaka ML, et al. Fit for
478 purpose: perspectives on rapid reviews from end-user interviews. *Systematic reviews*. 2017;6(1):32.
479 doi: 10.1186/s13643-017-0425-7. PubMed PMID: 28212677; PubMed Central PMCID:
480 PMC5316162.

481

FINAL DRAFT